UBS Maintains Buy on Axsome Therapeutics, Raises Price Target to $259
UBS analyst Ashwani Verma maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $251 to $259.
© Copyright 2026 | GROWTH Investing | All Rights Reserved
Important note:
Please note that we do not offer financial services such as investment advice, asset management, or financial brokerage. Our website is solely for providing information and educational content on modern financial strategies and stock analysis. All information presented on this website is for educational purposes and should not be construed as specific investment recommendations. We do not manage client funds and assume no responsibility for individual investment decisions. Each participant is responsible for their own financial decisions and should consult an independent financial advisor if necessary.
The successes, participation figures, and information presented here, provided by Growth Services LLC, are based on our own experiences and those of our clients in the field of stock and chart analysis. They should not be interpreted as an absolute guarantee or a firm promise. Individual success results can vary significantly and depend on numerous factors. The successes presented in our case studies and testimonials reflect the actual results of ourselves and our most dedicated participants and are intended as inspiration, not as a binding commitment. Our offering aims to equip you with the necessary knowledge and skills to perform optimally in the stock market. While we are committed to the success of each individual, we cannot guarantee specific results. Proactive participation and dedication from our clients are essential for success.
This site is not a part of the Facebook, Instagram website or Meta Platforms Inc. Additionally, This site is NOT endorsed by Meta Platforms in any way. FACEBOOK is a trademark of Meta Platforms, Inc.
This website is not affiliated with, endorsed by, or operated by Google LLC. Google is a registered trademark of Google LLC. Our service and offerings are not directly connected to the products or services of Google.
